Priya U. Kumthekar

Hematology Oncology | Neurology | Hematology

675 N St Clair St Ste 20-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 24, 2026

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.

Consideration of spatial companion biomarkers for targeted therapeutics in cancer: depatuxizumab mafodotin in glioblastoma.

Journal: JCI insight

Published: February 03, 2026

Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration.

Breaking Barriers in Leptomeningeal Disease: A SNO-ASCO Consensus Review on Clinical Trial Design and Basic Science Integration.

Journal: Neuro-oncology

Published: January 22, 2026

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents.

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents.

Journal: Neuro-oncology practice

Published: December 29, 2025

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

Journal: Journal of neuro-oncology

Published: December 03, 2025

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

Targeting Survivin: Now I Become Death, the Destroyer of Cells.

Targeting Survivin: Now I Become Death, the Destroyer of Cells.

Journal: International journal of molecular sciences

Published: October 28, 2025

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.

Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.

Journal: Research square

Published: October 03, 2025

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 03, 2025

Intracranial Metastases from Uterine Leiomyosarcoma: A Systematic Review and Case Illustration.

Intracranial Metastases from Uterine Leiomyosarcoma: A Systematic Review and Case Illustration.

Journal: Journal of clinical medicine

Published: July 29, 2025

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.

Journal: Nature medicine

Published: July 21, 2025

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Journal: Neuro-oncology advances

Published: June 24, 2025

Showing 1-12 of 122

Last Updated: 09/26/2026